Bosch J - Search Results

1

Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies.

de Mesquita FC, Guixé-Muntet S, Fernández-Iglesias A, Maeso-Díaz R, Vila S, Hide D, Ortega-Ribera M, Rosa JL, García-Pagán JC, Bosch J, de Oliveira JR, Gracia-Sancho J. de Mesquita FC, et al. Among authors: bosch j. Sci Rep. 2017 Jun 12;7(1):3255. doi: 10.1038/s41598-017-02866-y. Sci Rep. 2017. PMID: 28607430 Free PMC article.

2

Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis.

Bañares R, Moitinho E, Matilla A, García-Pagán JC, Lampreave JL, Piera C, Abraldes JG, De Diego A, Albillos A, Bosch J. Bañares R, et al. Among authors: bosch j. Hepatology. 2002 Dec;36(6):1367-73. doi: 10.1053/jhep.2002.36947. Hepatology. 2002. PMID: 12447861 Clinical Trial.

3

Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis.

Bellis L, Berzigotti A, Abraldes JG, Moitinho E, García-Pagán JC, Bosch J, Rodés J. Bellis L, et al. Among authors: bosch j. Hepatology. 2003 Feb;37(2):378-84. doi: 10.1053/jhep.2003.50053. Hepatology. 2003. PMID: 12540788 Clinical Trial.

4

Nitric oxide and portal hypertension.

González-Abraldes J, García-Pagán JC, Bosch J. González-Abraldes J, et al. Among authors: bosch j. Metab Brain Dis. 2002 Dec;17(4):311-24. doi: 10.1023/a:1021957818240. Metab Brain Dis. 2002. PMID: 12602508 Review.

5

Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.

Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodés J, Bosch J. Abraldes JG, et al. Among authors: bosch j. Hepatology. 2003 Apr;37(4):902-8. doi: 10.1053/jhep.2003.50133. Hepatology. 2003. PMID: 12668985

6

Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice.

Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Fernandez M, et al. Among authors: bosch j. Gastroenterology. 2004 Mar;126(3):886-94. doi: 10.1053/j.gastro.2003.12.012. Gastroenterology. 2004. PMID: 14988842

7

PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome.

Hernández-Guerra M, Turnes J, Rubinstein P, Olliff S, Elias E, Bosch J, García-Pagán JC. Hernández-Guerra M, et al. Among authors: bosch j. Hepatology. 2004 Nov;40(5):1197-202. doi: 10.1002/hep.20436. Hepatology. 2004. PMID: 15486923 Clinical Trial.

8

Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension.

Hernández-Guerra M, García-Pagán JC, Bosch J. Hernández-Guerra M, et al. Among authors: bosch j. J Clin Gastroenterol. 2005 Apr;39(4 Suppl 2):S131-7. doi: 10.1097/01.mcg.0000155513.17715.f7. J Clin Gastroenterol. 2005. PMID: 15758648 Review.

9

Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats.

Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodés J, Bosch J. Fernandez M, et al. Among authors: bosch j. J Hepatol. 2005 Jul;43(1):98-103. doi: 10.1016/j.jhep.2005.02.022. Epub 2005 Apr 25. J Hepatol. 2005. PMID: 15893841

10

Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis.

Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Gao H, Makuch R; Portal Hypertension Collaborative Group. Groszmann RJ, et al. Among authors: bosch j. N Engl J Med. 2005 Nov 24;353(21):2254-61. doi: 10.1056/NEJMoa044456. N Engl J Med. 2005. PMID: 16306522 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,948 results

Search Page